Bulk Orders By quote
Larger runs, institutional supply and custom timelines are priced by quote. Send the quantity and the timeline and we will come back with a number.
Ask about bulk
Metabolic Research
CBL-514 20 mg is supplied as a powder in a vial for laboratory research. CBL-514 is the name of an investigational small molecule studied in adipose-tissue research. The labeled amount is 20 mg per vial, not a concentration or a batch-assay result.
The compounds researchers order most, by verified order volume.
More ways to save
Larger runs, institutional supply and custom timelines are priced by quote. Send the quantity and the timeline and we will come back with a number.
Ask about bulkSelect a product option
Choose a size to check its batch and certificate. Published reports remain available below; check the lot before using a report.
Verified test results
Each batch is analyzed by Freedom Diagnostics, an independent third-party laboratory, before release. Below is the report for lot CBL01, summarized from the certificate the lab published.
This lot ships under its own published certificate. Open any certificate below, exactly as the lab released it.
Side by side
Important research notice
Not for human, veterinary, or food use. This product is sold exclusively for laboratory research purposes. It is not intended to diagnose, treat, cure, or prevent any disease, and has not been evaluated by the FDA.
All referenced publications and registries are sourced from peer-reviewed journals and official registries. They are provided for educational reference only and are not product claims.
By purchasing, you confirm you are a qualified researcher and will handle this product in accordance with all applicable laws and regulations.
Ready when you are
The lot on this page links to the signed certificate for that batch.
Research material
CBL-514 20 mg is supplied as a powder in a vial for laboratory research. CBL-514 is the name of an investigational small molecule studied in adipose-tissue research. The labeled amount is 20 mg per vial, not a concentration or a batch-assay result.
Caliway describes its investigational CBL-514 as a small-molecule drug candidate, rather than a peptide. Its development program examines localized subcutaneous fat reduction and other adipose-tissue conditions. Research on the developer's clinical formulation does not establish the identity, formulation, purity, safety or efficacy of this separately supplied research material. Disguised Alpha is not claiming affiliation with Caliway. Developer's CBL-514 research program.
Adipocytes are fat-storing cells; apoptosis is programmed cell death. Caliway's preclinical research describes changes in caspase-3 and the Bax/Bcl-2 ratio associated with adipocyte apoptosis. These findings explain the research interest in CBL-514, but do not demonstrate that an unverified commercial vial has the same composition or biological activity as the investigational formulation. Caliway's mechanism and study background.
The evidence includes early clinical studies of the developer's investigational formulation. Study design, population, measurement method and follow-up matter when comparing findings:
| 2022 Phase IIa study | Goodman and colleagues examined abdominal subcutaneous fat using ultrasound in an open-label study with random allocation. Its design and limited follow-up should be considered when interpreting the findings. PubMed PMID 35709509; DOI 10.1093/asj/sjac162. |
|---|---|
| 2025 placebo-controlled Phase II study | Gold and colleagues randomized 76 participants and evaluated abdominal subcutaneous fat with ultrasound. The reported results concern the study formulation and population. Injection-site reactions were the most common treatment-emergent adverse events. PubMed PMID 40037659; DOI 10.1093/asj/sjaf032. |
| 2026 Phase IIb study | Lorenc and colleagues randomized 108 adults and assessed clinician-reported and participant-reported abdominal fat ratings alongside MRI measurements. These endpoints differ from the ultrasound endpoints used in earlier studies. PubMed PMID 42159040; DOI 10.1093/asj/sjag092. |
Subcutaneous fat lies beneath the skin, while visceral fat surrounds internal organs. A 2026 EASD report described an exploratory MRI subgroup analysis drawn from CBL-514 Phase II trials. It should be read as preliminary subgroup evidence, separately from the trials' primary subcutaneous-fat endpoints. It is not proof of a predictable fat-loss result from this research product. Caliway's October 2, 2026 EASD report and study limitations.
| Product | CBL-514 |
|---|---|
| Labeled amount | 20 mg per vial |
| Format | Powder |
| SKU | CBL514 |
| Intended use | Laboratory research only |
Match the batch identifier on the supplied vial to its certificate of analysis (COA). Check the report's sample identity, laboratory, analytical method, report date and measured results. Labeled mass, measured content and chromatographic purity are different specifications. A product photograph, QR code or published study does not replace a matching batch report.
Batch CBL01: View the Freedom Diagnostics COA, accession 2611111049, reported November 13, 2026. This corrected report identifies curcumin and trans-resveratrol by LC-MS in four samples and reports passing endotoxin and elemental-impurity results, with no detectable microbial DNA by PCR. It does not report a purity percentage or quantified total content; the 20 mg product label is not a measured result from this certificate. PCR findings do not establish sterility. The report does not establish equivalence to Caliway’s investigational formulation. See the COA portal for the source report.
No. The 20 mg label states an amount per vial. A concentration in mg/mL also requires a defined solution volume; it cannot be inferred from the vial size or product name. No preparation or administration protocol is provided here.
Equivalence has not been established. Published results apply to the investigational material used in each study. A matching name does not prove that a separately supplied powder has the same formulation, manufacturing controls or clinical performance.
No. This listing is for laboratory research only, not for human consumption, self-administration, veterinary, diagnostic or therapeutic use. Clinical development information is research context and is not a claim that this product is an approved medicine.
Read 20 source-linked articles on CBL-514 identity, mechanism, clinical study design, evidence interpretation and research-material documentation. Each article separates the developer’s study findings from the specifications of this separately supplied laboratory material.
Explore the CBL-514 research guide, metabolic research collection, COA portal and research editorial standards. Sources reviewed October 30, 2026.
Retain the product label and lot number with the research record. Review the matching certificate of analysis for test coverage and reported results. Identity, analytical purity, measured content, sterility and endotoxin testing are distinct assessments; one does not establish the others.
Follow the supplied label and your laboratory’s validated handling and storage procedures. Record the vehicle, concentration and preparation date where relevant. Dry-material stability does not establish the shelf life of a prepared solution.
Match the compound or ingredient identity, format, labeled quantity and shipping lot. Similar names or different formulations should not be treated as equivalent.
Open the linked certificate for the assigned lot or use the COA portal. Check sample identity, methods, date and reported measurements. A report for another lot or formulation is not a substitute.
The current certificate is matched to the selected product option and assigned shipping batch.
Enable JavaScript to view the certificate for your selected option.
We share visit and purchase data with advertising partners to measure and show ads. Some US state laws, including California's, call that a sale or sharing of personal information. You can turn it off for this browser.
Ad sharing is on in this browser.
Saved in this browser only. For your account or other devices, email support@disguisedalpha.com. Privacy Policy